Two years with GIOIA ‘Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes’: A prospective, multicentre, quasi‐experimental study on sodium‐glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors in diabetes clinical practice

Documenti analoghi

• Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18‐month follow‐up of a randomized clinical trial
  di: Paola Caruso, et al.
  Pubblicazione: (2025)
• Comparison between sodium‐glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real‐world evidence study
  di: Hui‐Lin Sung, et al.
  Pubblicazione: (2024)
• Glucagon‐like peptide 1 receptor agonist for peripheral artery disease: Is it time to proceed?
  di: Dario Giugliano, et al.
  Pubblicazione: (2025)
• Risk of insulin initiation with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: A real‐world claims database study in Japan
  di: Ryo Suzuki, et al.
  Pubblicazione: (2025)
• The association between sodium glucose cotransporter‐2 inhibitors vs dipeptidyl peptidase‐4 inhibitors and renal outcomes in people discharged from hospital with type 2 diabetes: A population‐based cohort study
  di: Kate E. D. Ziser, et al.
  Pubblicazione: (2024)